Condition: Generalized Myasthenia Gravis · Sponsor: argenx
The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \<18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study. The participants will be in the study for up to 14 weeks.
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| Carolinas HealthCare System Neurosciences Institute - Neurology | Charlotte, North Carolina, United States | Recruiting |
| Neurology Rare Disease Center | Denton, Texas, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
| UZ Gent | Ghent, Belgium | Recruiting |
| Childrens Hospital of Eastern Ontario | Ottawa, Canada | Recruiting |
| Fakultni nemocnice Brno | Brno, Czechia | Recruiting |
| Fakultni nemocnice Ostrava | Ostrava, Czechia | Recruiting |
| AP-HM- Hôpital de La Timone | Marseille, France | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Recruiting |
| Hadassah Medical Center- Ein Kerem | Jerusalem, Israel | Recruiting |
| Schneider Children's Medical Center of Israel | Petah Tikvah, Israel | Recruiting |
| Tel Aviv Sourasky Medical Center Ichilov | Tel Aviv, Israel | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06392386